Golden State Equity Partners Has $906,000 Position in Kenvue Inc. $KVUE

Key Points

• Golden State Equity Partners increased its holdings in Kenvue Inc. by 68.2% during Q2, now owning 43,299 shares valued at $906,000.
• Kenvue recently declared a quarterly dividend of $0.2075, an increase from its previous dividend, with an annualized yield of 4.9%.
• The company's stock, trading at $16.96, experienced a 7.5% decline, and analysts have adjusted their price targets downward, with a consensus target of $24.04.

Golden State Equity Partners grew its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 68.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 43,299 shares of the company's stock after acquiring an additional 17,559 shares during the period. Golden State Equity Partners' holdings in Kenvue were worth $906,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Cambridge Investment Research Advisors Inc. grew its holdings in Kenvue by 4.0% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company's stock worth $2,545,000 after acquiring an additional 4,034 shares during the period. Arlington Partners LLC acquired a new stake in shares of Kenvue in the 2nd quarter valued at about $2,110,000. IFP Advisors Inc grew its stake in shares of Kenvue by 25.3% in the 1st quarter. IFP Advisors Inc now owns 15,278 shares of the company's stock valued at $369,000 after buying an additional 3,081 shares during the period. Vident Advisory LLC acquired a new stake in shares of Kenvue in the 1st quarter valued at about $520,000. Finally, AG2R LA Mondiale Gestion D Actifs acquired a new stake in shares of Kenvue in the 1st quarter valued at about $1,725,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Trading Down 7.5%

NYSE:KVUE opened at $16.96 on Tuesday. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $32.55 billion, a PE ratio of 22.92, a price-to-earnings-growth ratio of 2.63 and a beta of 0.83. The firm's 50 day moving average is $20.77 and its 200 day moving average is $22.00. Kenvue Inc. has a 12 month low of $16.89 and a 12 month high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, topping analysts' consensus estimates of $0.28 by $0.01. The company had revenue of $3.84 billion for the quarter, compared to analysts' expectations of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. Kenvue's revenue was down 4.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Sell-side analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were issued a $0.2075 dividend. This is a boost from Kenvue's previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Wednesday, August 13th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.9%. Kenvue's payout ratio is presently 112.16%.

Analysts Set New Price Targets

Several analysts have recently commented on KVUE shares. JPMorgan Chase & Co. reduced their target price on Kenvue from $27.00 to $26.00 and set an "overweight" rating for the company in a research note on Friday, July 25th. Royal Bank Of Canada reduced their target price on Kenvue from $24.00 to $22.00 and set a "sector perform" rating for the company in a research note on Friday, August 8th. Citigroup reduced their target price on Kenvue from $22.00 to $20.00 and set a "neutral" rating for the company in a research note on Tuesday, September 16th. Evercore ISI reduced their target price on Kenvue from $25.00 to $23.00 and set an "in-line" rating for the company in a research note on Monday, September 8th. Finally, Bank of America cut their price target on Kenvue from $27.00 to $25.00 and set a "buy" rating for the company in a research note on Tuesday, July 15th. Five research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $24.04.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.